At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot Study of Ribavirin for Patients With Recurrent/Metastatic (R/M) Human Papillomavirus (HPV)-Related Malignancies
In Brief
A clinical study evaluating Ribavirin for Human Papillomavirus (HPV)-Related Malignancies and Recurrent/Metastatic (R/M) Human Papillomavirus (HPV)-Related Malignancies. Completed, enrolled 12 participants across 6 sites.
Detailed Summary
The purpose of this study is to find out the effects, both good and bad, that a drug called ribavirin has on the patient and the cancer. Ribavirin has also been studied in clinical trials for patients with various types of cancer. These studies demonstrated that ribavirin can be safely given at higher doses than the dosing that is used as part of the treatment of hepatitis C. Ribavirin is known to target a protein called "4E" that turns on a central part which causes the cell to grow, called the ribosome. HPV-related cancers often have abnormally high levels of 4E. The purpose of this study is to evaluate if ribavirin may be a useful treatment for patients with advanced cancers that are related to HPV by blocking the activity of 4E.
Study Details
Timeline
Interventions
self-administer ribavirin 1400 mg PO BID (total dose, 2800 mg/day)